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Consistent Prebiotic Effect on Gut Microbiota With
Altered FODMAP Intake in Patients with Crohn’s
Disease: A Randomised, Controlled Cross-Over Trial of
Well-Defined Diets
Emma P. Halmos, BND, PGradDipBSc, PhD1,2, Claus T. Christophersen, MSc, PhD3,4, Anthony R. Bird, BAgrSc, MAgrSc, PhD3,
Susan J. Shepherd, BAppSci (Health Promotion), MND, PhD1,5, Jane G. Muir, BSc (Hons), PhD, PGradDip (Dietetics)1,2 and
Peter R. Gibson, MD, FRACP1,2
OBJECTIVES: Altering FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) intake has
substantial effects on gut microbiota. This study aimed to investigate effects of altering FODMAP intake on markers of colonic
health in patients with Crohn’s disease.
METHODS: After evaluation of their habitual diet, 9 patients with clinically quiescent Crohn’s disease were randomised to 21 days
of provided low or typical (“Australian”) FODMAP diets with≥ 21-day washout in between. Five-day fecal samples were collected at
the end of each diet and analyzed for calprotectin, pH, short-chain fatty acids (SCFA) and bacterial abundance. Gastrointestinal
symptoms were recorded daily.
RESULTS: Eight participants collected feces and were adherent to the diets. FODMAP intake differed across the three dietary
periods with lowohabitualoAustralian diet. SCFA, pH and total bacterial abundance remained unaltered, but relative abundance
was higher for butyrate-producing Clostridium cluster XIVa (P= 0.008) and mucus-associated Akkermansia muciniphila
(P= 0.016), and lower for Ruminococcus torques (P= 0.034) during the Australian compared with low FODMAP diet. Results
during habitual diet were similar to the low FODMAP intervention, but significantly different to the Australian diet. The diets had no
effects on calprotectin, but symptoms doubled in severity with the Australian diet (n= 9; Po0.001).
CONCLUSIONS: In clinically quiescent Crohn’s disease, altering dietary FODMAP intake is associated with marked changes in
fecal microbiota, most consistent with a prebiotic effect of increasing FODMAPs as shown in an irritable bowel/healthy cohort. This
strategy might be favorable for gut health in Crohn’s disease, but at the cost of inducing symptoms.
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INTRODUCTION
A diet low in FODMAPs (fermentable oligosaccharides,
disaccharides, monosaccharides and polyols) is increasingly
being used to manage symptoms in patients with irritable
bowel syndrome (IBS) and other functional gastrointestinal
conditions.1 Evidence of efficacy has been mounting world-
wide, with several observational trials as well as randomised
controlled trials showing the low FODMAP diet reduces
gastrointestinal symptoms to a satisfactory level.2–5 Most
recently, a carefully controlled randomised cross-over feeding
trial in which two diets of varying FODMAP content (and
matched for other nutrients) were provided to 30 IBS and 8
healthy subjects demonstrated that the low FODMAP diet
halved gastrointestinal symptoms compared with a typical
diet, and that the effects were specific to IBS subjects.6
Functional gastrointestinal symptoms are present three
times more commonly in patients with inflammatory bowel
disease (IBD) compared with the general population.7
Whether these symptoms represent true functional symptoms
or a manifestation of ongoing inflammatory disease (or other
cause) remains controversial. However, reducing FODMAP
intake in 72 IBD patients (including 52 with Crohn’s disease)
who had IBS-like symptoms and quiescent disease was
associated with considerable reduction of symptoms in
greater than one-half in a retrospective study.8 Only evidence
from a randomised placebo-controlled trial will truly ascertain
whether this benefit represents placebo effect or not.
One putatively negative effect of reducing FODMAP intake
is the change it induces in the gut microbiota in patients with
IBS and healthy controls. One study showed a reduction of the
relative abundance of Bifidobacteria in the feces.9 In a more
detailed analysis, a low compared with moderate (typical)
FODMAP intake was associated with one-third reduction in
the total abundance of fecal bacteria, specific relative
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reduction of the strongly butyrate-producing bacteria—Clos-
tridium cluster XIVa—by sevenfold and the mucus-associated
bacteria, Akkermansia muciniphila by fivefold, and a 1.5-fold
increase in the mucus-degrading bacteria Ruminococcus
torques, but no change in Faecalibacterium prausnitzii in the
27 IBS and six healthy subjects.10 Some of these findings
raise concern as many of the changes mimic those reported
to occur in patients with Crohn’s disease.11,12 Although it is
not known whether such dysbiosis is cause or effect of the
disease, if such changes in the microbiota also occur in
patients with Crohn’s disease when treated with the low
FODMAP diet, it might have deleterious effects.
The present study aimed, therefore, to investigate the
effects of two controlled diets varying only in FODMAP content
on fecal microbiota and other biomarkers of colonic health in a
randomised controlled, cross-over trial of patients with
quiescent Crohn’s disease. Secondary end points were to
compare fecal measures with those previously determined in
patients with IBS and healthy controls, to compare the fecal
indices with those associated with the patients’ habitual diet
and to assess the effect of varying FODMAP intake on
gastrointestinal symptoms. We hypothesized that a low
FODMAP diet will reduce abundance of total and specific
bacteria with putative good health effects and reduce
gastrointestinal symptoms compared with a diet of higher
FODMAP content in Crohn’s disease subjects and that data
will be similar to that seen in IBS and healthy subjects.
METHODS
Participants. Patients with quiescent Crohn’s disease accord-
ing to Harvey–Bradshaw Index of ≤513 who had been clinically
stable and were on stable therapy for at least 8 weeks were
recruited between March 2009 and May 2011 via advertise-
ments in gastroenterology clinics, community newspapers, and
through word of mouth. Subjects had not previously consulted
a dietitian for management of symptoms and were naive to the
low FODMAP diet. All subjects had celiac disease excluded by
duodenal biopsy and/or negative celiac serological testing
while consuming a gluten-rich diet and/or negative HLA-DQ2/
DQ8. Other exclusion criteria comprised previous abdominal
surgery and co-morbid conditions such as diabetes. Besides
their usual medications to maintain their stable IBD, patients
were not permitted to take pharmacological agents that might
alter their symptoms (such as laxatives or antidiarrheal agents).
Antibiotic or probiotic intake in the previous 2 months was also
an exclusion criterion.
Study protocol. The study protocol has been previously
described in detail, in which 27 IBS and 6 healthy subjects
underwent the same study protocol.6 Briefly, a gastroenter-
ologist assessed all patients prior to enrollment to verify the
diagnosis and disease activity, to ensure that inclusion and
exclusion criteria were met, and to document previous
investigations. For 1 week, participants recorded their
habitual dietary intake and symptoms. Gastrointestinal symp-
toms were measured daily using a 100 mm visual analog
scale, where 0 indicated no symptoms and 100 mm
represented worst symptoms ever experienced. The visual
analog scale score was used to measure overall gastro-
intestinal symptoms, abdominal pain, bloating, and passage
of wind as previously applied.14,15
Participants were then randomised according to a
computer-generated order to receive 21 days of a diet low in
FODMAPs or 21 days of a diet containing FODMAP content of
a typical Australian diet.16 Participants were blinded to the
diets and almost all food was provided. After this 21-day diet,
each participant entered a washout period of at least 21 days
in which they resumed their usual diet and then crossed-over
to the alternate diet. The second interventional diet was not
commenced until the symptoms had returned to the same
level as during their habitual diet, as determined by direct
questioning by a study investigator. From days 3–7 of the
participants’ habitual diet and days 17–21 of both interven-
tional diet periods, participants collected all feces passed. Just
prior to the fecal collection (morning of day 3 of habitual and
day 17 of interventional diets), participants swallowed a
capsule containing 24 radiopaquemarkers (Sitzmarks, Konsyl
Pharmaceuticals, MD). The time and date of capsule ingestion
was noted. Participants were instructed to collect each stool in
a supplied plastic container and to avoid urine contamination.
The containers were sealed and immediately stored in a
supplied portable −4 °C freezer. Each container was marked
with the date and time of stool passage. The freezers were
transported and delivered to the laboratory within the week
following the 5-day collection. Stools were X-rayed and
radiopaque markers counted to determine whole-gut transit
time based on time of stool passage.
All participants gave written informed consent prior to
commencement of the study. The study protocol was
approved by the Eastern Health and Monash University
Human Research and Ethics Committees.
Interventional diets. Almost all food, comprising three main
meals and three snacks daily, was provided. Detailed meal
plans specifying meals and quantities were supplied (given in
Supplementary Table S1 online). Participants were instructed
to eat to their appetite, and additional food lists were provided
so that they could purchase fresh perishable items and
additional food if participants wanted more. The supplemen-
ted foods contained at least one FODMAP for those following
the typical Australian diet or were low FODMAP of ≤0.5 g per
sitting on the low FODMAP diet. If participants ate out or
wanted to include foods that were not specified on the supplied
lists, they contacted the study investigator for guidance. The
study investigator (EPH) and university research chef, assisted
by two hospitality students, prepared all food in commercial
kitchens. Meals were cooked and provided as frozen complete
meals with instructions to thaw and warm either via microwave
or oven. They were free of charge and delivered to
participants’ homes weekly. All food consumed was recorded
in food diaries and adherence to the diet was based on these
records. If a participant consumed a high FODMAP meal
during the low FODMAP diet or had a day of no high
FODMAP-containing foods during the typical Australian diet,
that participant was considered non-compliant for that day. A
dietitian study investigator (EPH) determined non-compliance
based on consumed foods that were not supplied and
appeared to be either high or low FODMAP.
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The composition of the interventional diets was matched for
energy, macronutrients, sugars, starch and fiber. Because the
low FODMAP diet was also estimated to be lower in total fiber
and resistant starch, small quantities of psyllium and resistant
starch were added to the low FODMAP diet (daily average of
3 g psyllium and 5 g Hi-Maize 220 (National Starch &
Chemical Company, Bridgewater, NJ), respectively) to ensure
only FODMAP content was altered between the two diets and
both diets contained gluten. The meal plans were aimed to
provide an average 8 MJ daily and to meet the recommended
serves of all food groups according to the Australian dietary
guidelines.17 Both diets were also aimed to be low lactose
(o5 g per sitting).18 The low FODMAP diet aimed to keep
oligosaccharide, fructose in excess of glucose and polyol
content of o0.5 g each per sitting based on previously
published data15 and the typical Australian diet aimed to
mimic the FODMAP content previously estimated by a
validated food frequency questionnaire to be typically a daily
combined oligosaccharide and polyol content of 7.0 g.16
FODMAP content for all provided food underwent FODMAP
analysis via high-performance liquid chromatography and
enzymatic assays.
Fecal assessment. A single independent observer noted
the fecal frequency and weighed each stool. Stools were also
analyzed for fecal water content (FWC), whereby the 5-day
fecal samples were defrosted, pooled, and thoroughly mixed,
then transferred into a small specimen container. Each
sample was weighed and freeze-dried using Operon (Thermo
Fisher Scientific Australia, Scoresby, VIC, Australia), then
reweighed which enabled the calculation of wet weight and
dry weight. FWC was expressed as percentage.
The 5-day fecal samples were defrosted, pooled, and
mixed, then transferred into small specimen containers.
Samples were packed on dry ice and delivered to the
Commonwealth Scientific and Industrial Research Organisa-
tion (CSIRO) Animal, Food and Health Sciences (Adelaide,
SA, Australia), where they were thawed at 4 °C, then
transferred to an anaerobic chamber and aliquoted for further
analysis. All samples were stored at − 20 °C until analyzed for
SCFA and bacteria abundances. CSIRO investigators were
blinded to the treatments.
Fecal contents were analyzed in duplicate for SCFA by gas
chromatography and pH, as described previously.19 Concen-
trations of the total SCFA (sum of SCFA) and individual SCFA
including branched-chain fatty acids were reported as μmol/g
of fecal matter.
DNA was extracted from 0.25 g fecal matter using a repeat-
bead-beating plus column method.20 Total bacteria, butyrate-
producing bacteria that comprised Clostridium cluster IV
(Clostridium leptum group) including Faecalibacterium praus-
nitzii and Clostridium cluster XIVa (Clostridium coccoides
group) and Roseburia spp., traditionally prebiotic bacteria
(Lactobacilli and Bifidobacteria spp.), and mucus-degrading
bacteria (Akkermansia muciniphila, Ruminococcus gnavus
and Ruminococcus torques) were analyzed. These bacteria
were chosen for analysis to specifically examine the role of
dietary FODMAPs on bacteria thought to be markers of
inflammation and bacteria thought to have health benefits.
Total bacterial abundance, and absolute and relative
abundance of specific bacteria were measured to analyze
the absolute and proportional changes in bacteria putatively
beneficial or detrimental to health, thereby indicating the
relative degree of prebiosis. Detailed methodology of the
primers and optimized quantitative real-time PCR conditions
has been previously outlined in detail.10
Pooled samples also underwent analysis for the content
of calprotectin. This was assessed in duplicate by ELISA
using a commercial kit (Buhlmann EK-Cal, Schönenbuch,
Switzerland) as per manufacturer’s instructions. The results
were expressed as an average of duplicate samples as
μg/g feces.
End points. The primary end point was the difference in fecal
microbiota on the low FODMAP compared with typical
Australian diets as measured by total and specific bacterial
abundance in the Crohn’s disease participants. Secondary
end points included differences in fecal pH, total and specific
fecal SCFA concentration, gastrointestinal symptoms, fecal
frequency, fecal weight, FWC, whole-gut transit time, compar-
ison of data during interventional diets with subjects’ habitual
diet, and comparison of data from Crohn’s disease subjects to
IBS/healthy subjects who followed the same study protocol.
Statistical analysis. Power calculations were based upon a
cohort of patients with IBS, of which the data have been
previously published.6 Crohn’s disease participants were
recruited up until the adequate sample size of IBS partici-
pants was reached. At that time, nine Crohn’s disease
participants had completed the study. Data were analyzed on
an intention-to-treat basis.
All descriptive data, including participant demographics,
were parametric and presented as mean and 95% confi-
dence interval (CI) unless otherwise specified. Data of fecal
characteristics were parametric, except for bacterial abun-
dance, which were normalized by log10 conversion before
further analysis. All raw fecal characteristic data were
presented as mean (95% CI), unless otherwise specified.
Differences of fecal characteristics between the interventional
diets were shown as a ratio of low FODMAP compared with
typical Australian diet and did not fit a normal distribution.
Hence, changes in bacterial abundance and SCFA
were compared between diets by Wilcoxon matched-pairs
signed rank test. Bacterial abundance of Crohn’s disease and
IBS/healthy cohorts were compared using Mann–Whitney
test. A P-value≤ 0.05 was considered statistically significant.
All statistical tests, unless specified, were analyzed with
GraphPad Prism version 6 (La Jolla, CA) and SPSS version 20
(IBM Corporation, Armonk, NY) programs. Comparisons in
microbiological data were qualitatively made with the results
previously published for the cohort of healthy subjects and
patients with IBS.
RESULTS
Participants. The nine participants completed all dietary
arms, but one did not collect feces. The subjects included six
women (67%) and had a median (interquartile range) age of
35 (29–41) years and body mass index 24 (23–27) kg/m2.
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Four subjects had colonic disease and the remaining five had
ileo-colonic disease, one of whom also had upper gastro-
intestinal Crohn’s disease. Median (interquartile range) time
since diagnosis was 7 (3.5–13) years. As shown in Figure 1,
fecal calprotectin was also similar across the three phases
of the study, but, in three subjects, it was consistently
4150 μg/g, indicating active disease despite the Harvey–
Bradshaw Index beingo5. Four subjects were not on any
medications to manage their Crohn’s disease, one subjects
was taking balsalazide, one was taking azathioprine mono-
therapy, one mesalazine and azathioprine, and two were on
anti-tumour necrosis factor monotherapy therapy (infliximab
and adalimumab). No changes in medication occurred during
the study.
Dietary adherence during the interventional diets was
good with all participants adhering to the typical Australian
diet, and all except one participant (the participant who did
not collect fecal samples) adhering to the low FODMAP diet
for at least 17 out of the 21-day interventional period. The
only measured nutrient that differed between the two
interventional diets was the average daily intake of FODMAPs
(Table 1).
Symptoms. The severity of overall gastrointestinal symp-
toms was significantly less on the last 14 days of the low
FODMAP diet at mean (95% CI) 13.5 (5.9–21.1) mm
compared with the last 14 days of the typical Australian diet
24.8 (12.6–37) mm (Po0.001; repeated measures ANOVA
(see Figure 2a)). This represented a fall of 11.4 (0.85–21.9)
mm. As illustrated in Figure 2b–d, similar results were seen in
abdominal pain (fall of 12.0 (7.5–16.4) mm), bloating, (fall
of 13.8 (6.0–21.6) mm), and passage of wind (fall of 15.5
(11.9–19.0) mm). The paired differences in symptoms were
similar in those who received the low FODMAP diet first
or second (data not shown).
Fecal indices during the interventional diets. The results
of complete fecal samples that were collected over the last
5 days of each dietary period are shown in Table 2. The one
participant who did not collect fecal samples could not be
included in fecal data. There were no significant differences
in fecal frequency, weight, FWC, or whole-gut transit time
across the dietary periods. There were no differences in
fecal pH, total or specific fecal SCFA across diets (Table 3).
Molar proportions of the major SCFA were also unchanged
(data not shown).
Total bacterial abundance was similar with the two inter-
ventional diets (Table 4). During the typical Australian diet,
absolute and relative abundance of the butyrate-producing
C. cluster XIVa and the mucus-associated A. muciniphila
were greater compared with those associated with the low
Figure 1 Mean fecal calprotectin (μg/g) analyzed in duplicate from pooled
samples of 8 subjects with Crohn’s disease following their habitual diet and
17–21 days of low FODMAP and typical Australian diets. A limit of 150 μg/g is
considered quiescent disease as indicated by a dotted line. No differences were
observed between diets.
Table 1 The mean daily nutrition information of provided low and typical Australian FODMAP interventional diets and habitual diets of subjects with Crohn’s disease
Per day Typical Australian diet Low FODMAP diet P-value Habitual diet
Energy (MJ) 8.17 (7.37–8.97) 8.17 (7.09–9.24) 0.979 8.90 (7.47–10.3)
Protein (g) 96.1 (84.7–107) 98.1 (83.7–113) 0.361 89.2 (70.0–108)
Fat (g) 71.6 (49.4–93.8) 74.4 (51.9–97.0) 0.337 79.2 (62.1–96.4)
Carbohydrate (g) 219 (180–259) 215 (181–249) 0.579 254 (216–292)
Sugars (g) 120 (103–137) 122 (106–139) 0.468 113 (92.4–134)
Starch (g) 94.0 (52.8–135)* 95.4 (59.7–131)† 0.783 153 (110–197)*†
Fiber (g) 25.9 (21.3–30.6) 23.4 (18.7–28.2) 0.085 22.1 (15.2–28.9)
Oligosaccharides (g) 5.49 (2.34–8.65) 1.57 (0.47–2.66)* 0.009 3.45 (2.31–4.60)*
Polyols (g) 4.21 (2.57–5.85)* 0.20 (–0.04–0.44)† 0.002 1.30 (0.52–2.07)*†
Lactose (g) 1.35 (0.20–2.49)* 0.05 (–0.01–0.10)† 0.033a 9.11 (5.20–13.0)*†
Fructose in excess of glucose (g)b 12.7 (8.06–17.3) 1.24 (0.41–2.07) 0.001 —
Total FODMAPs (g)b 23.7 (16.9–30.6) 3.05 (1.86–4.25) o0.001 —
Gluten Present Present Present
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols.
All nutrients were estimated by the FoodWorks program, except for the FODMAP content of the typical Australian diet and low FODMAP diets, which were analyzed by
high-performance liquid chromatography and enzymatic assays. Interventional diets were analyzed by paired t-tests.
Statistically significant differences are shown in bold and are based on P≤ 0.05.
Differences between *habitual diet and †interventional diets.
aAlthough there is a significant difference in lactose between the interventional diets, 5 g lactose per sitting is considered to be well-absorbed and tolerated in majority
of people.18
bFructose in excess of glucose, and therefore total FODMAPs, cannot be estimated by the FoodWorks program for the habitual diet.
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FODMAP diet (Table 4 and Figure 3). Relative abundance
of R. torques was decreased on the typical Australian diet
in comparison with the low FODMAP diet (Table 4 and
Figure 3b). The effects on these bacteria were similar in those
who received the low FODMAP diet first or second (data not
shown). There were no significant differences in absolute and
relative abundance of Lactobacilli and Bifidobacteria spp.
between the two controlled diets.
Habitual diets. Participants’ habitual diets were similar
to the two interventional diets, except for starch intake,
which was higher than in the interventional diets. None
of the subjects were restricting dietary FODMAPs during
their habitual diet, but oligosaccharides and polyols were
not as high as the typical Australian diet (Table 1). Lactose
was unrestricted during the habitual diet. Compared with
symptoms while consuming the participants’ habitual diet
(12.5 (8.7–16.3) mm), the low FODMAP diet did not alter
the severity of symptoms (P=0.285), but, the typical
Australian diet increased overall gastrointestinal symp-
toms (Po0.001; Figure 2a) and similar patterns were
seen with the other measured gastrointestinal symptoms
(Figure 2b–d).
There were no differences in fecal pH, total or specific fecal
SCFA on the habitual diet compared with the provided diets
(Table 3). Absolute and relative abundance of bacteria in
association with the habitual diet are shown in Table 4. Total
bacterial abundancewas similar on the habitual diet compared
Figure 2 Mean daily symptoms in subjects with quiescent Crohn’s disease rated using 100 mm visual analog scale (VAS) for (a) overall gastrointestinal symptoms,
(b) abdominal pain, (c) bloating, and (d) passage of wind during habitual diets and interventional low FODMAP and typical Australian diets. Symptoms were significantly lower
on both habitual and low FODMAP diets compared with the typical Australian diet (see text).
Table 2 Daily fecal frequency, weight, fecal water content, and whole-gut transit time in eight subjectswith quiescent Crohn’s disease after following a habitual diet and
a low FODMAP and typical Australian diet for 17–21 days
Subject group Diet Fecal frequency
(number of stool per day)
Fecal weight
(g per day)
Fecal water content
(percentage of total weight)
Whole-gut transit
time (h)
0 1–2 3–4
Crohn’s disease
(n=8)
Habitual 0 6 2 P=0.626 159 (86–232) P=0.271 78.5 (73.7–83.3) P=0.967 33.4 (23.0–43.8) 0.794
Australian 1 6 1 151 (89–214) 76.9 (70.4–83.4) 43.5 (23.0–64.0)
Low FODMAP 0 7 1 149 (88–211) 77.7 (72.3–83.1) 39.2 (23.5–54.8)
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols.
Data are presented as mean (95% CI); χ2-test for fecal frequency and Friedman test for fecal weight, fecal water content, and whole-gut transit time.
Prebiotic Effects of FODMAPs in Crohn’s Disease
Halmos et al.
5
Clinical and Translational Gastroenterology
with the other two dietary periods. However, the habitual diet
was similar to the low FODMAP diet and had a reduced
absolute and relative abundance of the butyrate-producing
C. cluster XIVa and the mucus-associated A. muciniphila
compared with the typical Australian diet (Table 4). The
habitual diet also had a lower relative abundance of
Lactobacilli compared with that with the low FODMAP diet
(P=0.039; Wilcoxon matched-pairs signed rank test).
Bacterial abundance compared to IBS and healthy
subjects. The Crohn’s disease subjects had similar bacterial
profiles during all three dietary periods than those seen from
a combined IBS and healthy population who had followed a
study of identical protocol (habitual diet shown in Figure 4),
although the low FODMAP diet did not reduce total bacterial
load as seen in the IBS/healthy cohort.10 It is evident that
two Crohn’s disease subjects had marked reduction in
abundance of C. cluster IV and F. prausnitzii on their habitual
diets (Figure 4). One had a fecal calprotectin of 1,460 μg/g.
The other bacterial groups studied were present in similar
absolute and relative abundance.
DISCUSSION
Altering the carbohydrate content of the diet potentially alters
the gut microbiota, which is of great interest in a Crohn’s
disease population that is already at risk of dysbiosis. Literature
would suggest that the bacterium of most relevance in a
Table 3 Fecal pH, total and specific SCFA (μmol/l) on pooled 5-day fecal samples after following a habitual diet and low FODMAP and typical Australian diets for
17–21 days in 8 subjects with quiescent Crohn's disease in a cross-over trial
Measure Typical Australian diet Low FODMAP diet P-value Habitual diet
pH 6.80 (6.36–7.24) 6.92 (6.42–7.43) 0.313 6.92 (6.62–7.22)
Total SCFA 68.6 (45.8–91.5) 78.1 (57.5–98.6) 0.195 76.6 (62.4–90.8)
Butyrate 11.3 (5.4–17.3) 13.0 (6.8–19.3) 0.195 12.0 (6.1–17.9)
Propionate 12.6 (6.1–16.4) 15.1 (10.3–19.8) 0.148 16.1 (11.4–20.7)
Acetate 38.0 (25.1–50.8) 42.9 (29.0–56.8) 0.195 42.2 (34.1–50.4)
Isobutyratea 2.27 (0.98–3.56) 2.10 (1.12–3.08) 1.00 1.95 (1.11–2.79)
Isovalerate 3.13 (1.09–5.17) 3.06 (1.49–4.63) 0.844 2.82 (1.35–4.29)
Valeratea 2.05 (0.28–3.83) 2.71 (1.67–3.74) 0.438 1.90 (0.52–3.29)
Caproatea 0.90 (−0.42–2.21) 0.86 (0.48–1.23) 1.00 1.35 (−1.98–4.64)
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols; SCFA, short-chain fatty acids.
Interventional diets were analyzed by Wilcoxon matched-pairs signed rank test. There were no statistically significant differences seen based on P≤ 0.05.
aDue to difficulties in analysis for isobutyrate, n=7; valerate, n= 5; and caproate, n= 3.
Table 4 Absolute and relative bacterial abundance on pooled fecal samples after following a habitual diet and low FODMAPand typical Australian diets for 17–21 days
in cross-over trial (n= 8)
Measure Bacteria Australian diet Low FODMAP diet P-value Habitual diet
Absolute abundance (Log10
copies of 16S rRNA gene/g)
Total bacteria 9.48 (9.17–9.79) 9.53 (9.20–9.86) 0.641 9.60 (9.19–10.0)
Clostridium cluster IV 7.58 (6.65–8.50) 7.59 (6.49–8.68) 0.773 7.56 (6.34–8.78)
F. prausnitzii 6.79 (5.77–7.80) 6.81 (5.64–7.98) 1.00 6.96 (5.73–8.20)
Clostridium cluster XIVa 8.73a (8.42–9.03) 7.94 (7.55–8.34) 0.008 8.01 (7.57–8.46)
Roseburia 7.02 (6.03–8.00) 6.95 (5.80–8.09) 0.313 7.16 (6.32–8.00)
Lactobacilli 6.11 (5.70–6.52) 6.48 (6.01–6.96) 0.078 6.29 (5.84–6.73)
Bifidobacteria 7.33 (6.87–7.80) 7.12 (6.54–7.70) 0.078 7.33 (6.60–8.07)
A. muciniphilab 5.08a (3.19–6.97) 3.75 (1.97–5.54) 0.016 4.11 (2.44–5.78)
R. gnavus 7.11 (6.79–7.44) 7.20 (6.90–7.50) 0.547 7.26 (6.81–7.71)
R. torques 5.65 (4.65–6.65) 6.13 (5.28–6.99) 0.195 6.14 (5.41–6.86)
Relative abundance
(percentage of total bacteria)
Clostridium cluster IV 2.70 (0.63–4.78) 2.69 (0.93–4.46) 0.383 3.02 (0.77–5.26)
F. prausnitzii 0.47 (0.21–0.72) 0.66 (0.14–1.19) 0.250 0.81 (0.09–1.54)
Clostridium cluster XIVa 19.2a (11.2–27.3) 2.81 (1.88–3.74) 0.008 2.90 (1.80–4.01)
Roseburia 0.94 (0.21–1.68) 0.81 (0.18–1.44) 1.00 0.68 (0.23–1.13)
Lactobacilli 0.06 (0.01–0.10) 0.17a (−0.01 to 0.35) 0.195 0.06 (0.03–0.08)
Bifidobacteria 1.27 (0.11 to 2.43) 1.11 (−0.55 to 2.76) 0.383 2.09 (−0.54 to 4.71)
A. muciniphilab 0.15a (− 0.05 to 0.35) 0.01 (−0.02 to 0.04) 0.016 0.01 (− 0.01 to 0.03)
R. gnavus 1.17 (−0.25 to 2.59) 1.39 (−0.38 to 3.17) 0.461 2.26 (−1.51 to 6.03)
R. torques 0.10 (− 0.04 to 0.24) 0.16 (−0.03 to 0.34) 0.039 0.15 (−0.05 to 0.35)
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols.
Interventional diets were analyzed by Wilcoxon matched-pairs signed rank test.
Statistically significant differences are shown in bold and are based on P≤ 0.05.
*Differences between habitual diet and interventional diets.
aPo0.05 compared with habitual diet; Wilcoxon matched-pairs signed rank test.
bDue to difficulties in microbial analysis for A. muciniphila, one subject could not be included so n= 7.
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Crohn’s disease population is F. prausnitzii. Reduced mucosal
F. prausnitzii has predicted onset of active disease21 and is
altered in new-onset Crohn’s disease,22 and fecalF. prausnitzii is
reduced in unaffected siblings of patients with Crohn’s disease,
thought to be at high risk of Crohn’s disease development.23
Similarly, in vitro and animal models suggest that A. muciniphila
may also predict Crohn’s disease activity.12,24,25 Indeed,
two subjects with Crohn’s disease in the present study had, in
comparison with our own comparator IBS/healthy cohort, a
markedly lower absolute and relative abundance ofC. cluster IV
and F. prausnitzii (Figure 4), together with a reduced absolute
and relative abundance of A. muciniphila.One of them also had
an increased absolute and relative abundance of R. gnavus.
This pattern has been previously reported to be associated with
active disease.11 Evidence of fecal dysbiosis may be present in
these two Crohn’s disease subjects.
The patterns of change in the measured bacteria
were almost identical to those observed in the IBS/healthy
cohort who underwent the same interventions and had
identical methodological dissection of the fecal microbiota10
Figure 3 Absolute bacterial abundance of subjects with Crohn’s disease during the provided low FODMAP and typical Australian diets, presented as ratio of low-to-typical
Australian diet for (a) absolute bacterial abundance and (b) relative bacterial abundance. Data comparing low and typical Australian diets were analyzed by Wilcoxon matched-
pairs signed rank test and statistically significant differences between the diets are indicated with a box based upon P≤ 0.05. Due to difficulties in analysis A. muciniphilia n= 7
for provided diets.
Figure 4 Bacterial abundance of subjects with Crohn’s disease compared with irritable bowel syndrome and healthy subjects during their habitual diet. Data are presented as
(a) absolute bacterial abundance and (b) relative bacterial abundance. Due to difficulties in analysis A. muciniphilia n= 7 for provided diets. Subjects with fecal
calprotectin4250 μg/g are indicated with a star. No differences in bacterial abundance were observed between the subject groups.
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(Figure 4). It is reassuring that the same dietary manipula-
tions of FODMAPs produce consistent effects irrespective
of the underlying disease state. Few patients with active
disease were found in the current cohort as they were
selected on the basis of clinical remission. Nevertheless,
the three who had active intestinal disease on the basis
of an elevated fecal calprotectin also had the same patterns
of change in microbiota in response to dietary change
(Figure 3).
The typical Australian diet had a mean oligosaccharide
content of 2.04 g/day and a polyol content of 2.91 g/day
(although only perhaps 30% of that might have been expected
to reach the colonic bacteria26) above the habitual diet. It is
likely that this relatively small increase in dietary components
that have prebiotic effects were responsible of the changes in
microbiota in the typical Australian dietary arm, especially as
an increase in oligosaccharides of as little as 2.5 g daily can
induce a prebiotic effect.27 The prebiotic effect may have been
exaggerated because the comparator arm had such a low
FODMAP intake. This confounder, that is, the background
habitual dietary FODMAP intake, has not been previously
considered in clinical trials of prebiotics. This is so important as
the concept of prebiotics is that there is a ceiling effect; doses
above this will lead to non-specific, fermentative effects only.
This is consistent with the randomised double-blinded study
of fructo-oligosaccharides supplementation in a large cohort
of patients with Crohn’s disease in which no prebiotic effect
was documented, disease activity did not change, but symp-
toms likely related to fermentation events were worsened.28
The usual FODMAP intake of the nine subjects with
Crohn’s disease was lower than expected, on the basis of
a previous study of the FODMAP intake of a healthy
population.16 None of the recruited patients had intentionally
altered their habitual diet and were selected on the basis of
being ‘FODMAP naive’. However, there are survey data
showing 57% of patients with ulcerative colitis restrict food
during remission, mostly to alleviate symptoms29 and a case-
control study showed that patients with Crohn’s disease who
were apparently naive to the low FODMAP diet eat lower
amounts of fructans.30
The differences in microbiota between the low FODMAP
and the habitual diets were characterized by three observa-
tions. First, the higher relative abundance of Lactobacilli
on the low FODMAP diet, a finding that was not expected,
was, in view of its small effect size, probably a chance
observation due to multiple comparisons with small number
of subjects. Secondly, the habitual diet was associated with
total bacterial abundance that was similar to that seen with
the low FODMAP diet. This was very different to the
effects observed in the IBS/healthy cohort in which the low
FODMAP diet reduced total bacterial abundance. Whether
this is a disease effect or due to differences in the habitual diet
cannot be ascertained. Thirdly, there was no relative expan-
sion of any of the targeted specific bacteria, even though there
was greater than twofold more FODMAPs consumed. It is
unlikely that inclusion of small amounts of psyllium and
resistant starch in the low FODMAP diet could have exerted
this effect on the microbiota as they were also included in
the diets of the IBS/healthy cohort. These issues need
further study.
The primary endpoint of comparison of the controlled low
FODMAP and typical Australian diets showed a considerable
difference in C. cluster XIVa and A. muciniphila, bacterial
populations with favorable health effects31,32 that have great
significance in Crohn’s disease as a reduced production of
butyrate and their precursors is likely to support an inflamma-
tory environment.11 In patients with ulcerative colitis, butyrate
enemas may be effective in reducing disease activity33
although similar studies in patients with Crohn’s disease have
not been reported. The general consensus on A. muciniphila
is that it supports healthy bacteria adjacent to the epi-
thelium,12,24,25,31 which again, may be conducive to reducing
risk of inflammation. The lower relative abundance of
A. muciniphila on the low FODMAP diet was also accom-
panied by a higher relative abundance of R. torques as
previously observed by Png et al.12 R. torques is commonly
seen in higher abundance in patients with IBD,11,12 suggests
that a reduced FODMAP intake may encourage an environ-
ment that is unfavorable to health. Altering dietary FODMAPs
did not change the abundance of Lactobacilli and Bifido-
bacteria spp., which are traditionally thought to be markers of
prebiotic activity. Again, this seems consistent with a previous
observation in patients with Crohn’s disease who received
fructo-oligosaccharides supplementation, in which no specific
increase in fecal Bifidobacteria spp. ahead of total bacterial
abundance was observed.28 The lack of change in fecal SCFA
in this study does not support the notion that a low FODMAP
diet reduces butyrate production.9 Likely reasons for this is
that fecal SCFA does not accurately reflect SCFA production
as 495% of SCFA are rapidly absorbed and metabolized
and SCFA production occurs mostly in the proximal colon.34
These data suggest that if, patients with Crohn’s disease
had a FODMAP intake similar to that of the designed typical
Australian diet, their microbiome would approach a putatively
better structure. The observed differences in fecal indices
between the different diets were almost identical to those
observed in IBS/healthy patients undergoing the same trial
procotol,10 except for the differences in overall bacterial
abundance observed in IBS/healthy control group. This may
be because the majority of patients in the IBS/healthy cohort
had IBS. Dysbiosis has been described in some studies in
patients with IBS.35,36 Unfortunately, this study was not
powered to observe differences between Crohn’s disease
and healthy subjects.
The subjects were relatively asymptomatic on their habitual
diet and remained so on the low FODMAP diet, but
gastrointestinal symptoms significantly increased with the
higher FODMAP intake on the typical Australian diet without
changing disease activity. The efficacy of the low FODMAP
diet in managing functional gastrointestinal symptoms in
patients with IBS is well-established,1 but published evidence
for the efficacy of this treatment in patients with quiescent IBD
and IBS-like symptoms is limited to an observational study.8
The increase in gastrointestinal symptoms with increasing
dietary FODMAP intake without change to disease activity, as
shown by stable fecal calprotectin, provides evidence that
FODMAPs do induce functional symptoms in patients with
Crohn’s disease. The increase in symptoms of 410 mm on
the typical Australian diet was considered clinically significant
based on previous literature.6 This might be considered as
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evidence that there is merit in reducing dietary FODMAPs in
patients with Crohn’s disease and co-existing functional
gastrointestinal symptoms. However, such efficacy can
only be more definitively proven by studying patients with
quiescent Crohn’s disease who are complaining of functional
symptoms.
A major limitation of the current study is the small number of
patients examined. Most importantly, this can lead to type I
errors occurring in multiple comparisons. Indeed, correction
for multiple comparisons using, for example, the false-
discovery rate methodology yields a P-value threshold
(0.006) that is not even reached by comparison of the relative
abundance ofC. clusterXIVa between the two controlled diets,
despite the relative abundance being markedly lower in
association with the low FODMAP diet in every patient with
wide differences in 95% CIs and a P-value of 0.008. The
confidence that the differences observed are not errors lies in
the almost identical pattern of differences that were seen in a
larger sample of non-inflamed subjects (healthy and IBS),
wherein correction for multiple comparisons did not negate the
statistical significance of the findings.
In conclusion, the findings show that altering the FODMAP
content with a standardised diet consistently and predictably
altered the faceal microbiota in similar ways that those diets
did in a cohort of healthy subjects and patients with IBS and
Crohn’s disease, despite the presence of dysbiosis. When
compared with the fecal findings in association with the
patients’ habitual diets, the changes better reflected a
prebiotic effect of increasing FODMAPs in this Crohn’s
disease cohort who had a relatively low habitual FODMAP
intake. Increasing FODMAP intake did induce gastro-
intestinal symptoms of greater severity without change in
inflammatory activity. Although these results might support the
use of a low FODMAP diet in an attempt to reduce presumed
functional gastrointestinal symptoms in patients with
Crohn’s disease, caution should be exercised in long-term
strict restriction of FODMAP intake as the implications
of the loss of the prebiotic effects of FODMAPs on disease
activity and other aspects of colonic health remain unknown.
On the contrary, the findings support a modest increase
in FODMAP intake in putatively improving the colonic
microenvironment.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ A low FODMAP diet (LFD) reduces symptoms in patients
with irritable bowel syndrome (IBS).
✓ A LFD is frequently applied to patients with Crohn’s disease
(CD) and functional symptoms.
✓ A LFD reduces abundance of total fecal bacteria in IBS and
healthy subjects.
✓ A LFD reduces specific bacteria with putative health
benefits in IBS and healthy subjects.
WHAT IS NEW HERE
✓ In patients with CD, a LFD does not reduce total fecal
bacterial abundance.
✓ Altering FODMAPs in patients with CD has marked
changes in specific fecal bacteria.
✓ Changes in specific fecal bacteria of CD subjects is
consistent with IBS/healthy subjects.
✓ A LFDmay be beneficial in reducing functional symptoms in
patients with CD.
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